HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NPLC 0393

a PP2Calpha activator; structure in first source

Also Known As:

NPLC-0393; NPLC0393

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Saponins: 2867
    - NPLC 0393: 4

Experts

1.	Fang, Shanhua: 2 articles (01/2020 - 04/2019)
2.	Ji, Feihong: 2 articles (01/2020 - 04/2019)
3.	Liu, Qian: 2 articles (01/2020 - 04/2019)
4.	Wang, Kuifeng: 2 articles (01/2020 - 04/2019)
5.	Zhou, Hu: 2 articles (01/2020 - 04/2019)
6.	Zhu, Jiansheng: 2 articles (01/2020 - 04/2019)
7.	Hu, Lihong: 2 articles (04/2019 - 12/2010)
8.	Shen, Xu: 2 articles (04/2019 - 12/2010)
9.	Huang, Hui: 1 article (01/2020)
10.	Gao, Daming: 1 article (04/2019)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 10/01/2023 - "NPLC0393 from Gynostemma pentaphyllum ameliorates Alzheimer's disease-like pathology in mice by targeting protein phosphatase magnesium-dependent 1A phosphatase."
2.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2020 - "In conclusion, these results provide information on the mechanism underlying the antifibrotic effect of NPLC0393 and shed new light on the potential therapeutic function of the TGF-β1/NDRG2/MAPK signaling axis in liver fibrosis." 12/06/2010 - "Our findings suggested that PP2Cα activation might be an attractive new strategy for treating liver fibrosis while the small molecular activator NPLC0393 might represent a lead compound for antifibrogenic drug development. " 01/01/2020 - "In this study, a TMT-based quantitative proteomic study using a carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis was performed to identify the potential target of NPLC0393. "
3.	Cognitive Dysfunction 10/01/2023 - "NPLC0393 was administered daily in vivo by intraperitoneal injection for 3 months and its amelioration on the cognitive impairment in 3×Tg-AD mice was assessed by new object recognition (NOR), Y-maze, Morris water maze (MWM), and elevated plus-maze (EPM) tests. "
4.	Tauopathies 10/01/2023 - "Moreover, NPLC0393 suppressed tauopathy by inhibiting tau hyperphosphorylation through PPM1A/NLRP3/tau axis and promoting microglial phagocytosis of tau oligomers through PPM1A/nuclear factor-κB/CX3CR1 pathway. "
5.	Fibrosis (Cirrhosis) 04/01/2019 - "Consistently, in vivo and in vitro knockdown of MAT2A alleviates CCl4- and TGF-β1-induced HSC activation, whereas in vivo overexpression of MAT2A facilitates hepatic fibrosis and abolishes therapeutic effect of NPLC0393. " 04/01/2019 - "We found that methionine adenosyltransferase 2A (MAT2A) is significantly upregulated in the CCl4-induced fibrosis mice, and application of NPLC0393, a known small molecule inhibitor of TGF-β1 signaling pathway, inhibits the upregulation of MAT2A. " 04/01/2019 - "We performed pharmacoproteomic profiling of the mice liver tissues from control, carbon tetrachloride (CCl4)-induced fibrosis and NPLC0393 administrated groups. "

Related Drugs and Biologics

1.	Phosphoprotein Phosphatases (Phosphatases, Protein)
2.	Phosphoric Monoester Hydrolases (Phosphatases)
3.	Magnesium
4.	Carbon Tetrachloride (Tetrachloromethane)
5.	Therapeutic Uses
6.	Methionine Adenosyltransferase

Related Therapies and Procedures

1.	Intraperitoneal Injections